-
1
-
-
33744762777
-
Bisphosphonates: From bench to bedside
-
Russell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006;1068:367-401.
-
(2006)
Ann N Y Acad Sci
, vol.1068
, pp. 367-401
-
-
Russell, R.G.1
-
2
-
-
0014029045
-
Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis
-
Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature. 1966;212(5065):901-903.
-
(1966)
Nature
, vol.212
, Issue.5065
, pp. 901-903
-
-
Fleisch, H.1
Russell, R.G.2
Straumann, F.3
-
3
-
-
0014902988
-
The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats
-
Russell RG, Muhlbauer RC, Bisaz S, Williams DA, Fleisch H. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res. 1970;6(3):183-196.
-
(1970)
Calcif Tissue Res
, vol.6
, Issue.3
, pp. 183-196
-
-
Russell, R.G.1
Muhlbauer, R.C.2
Bisaz, S.3
Williams, D.A.4
Fleisch, H.5
-
4
-
-
0032722149
-
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
-
Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104(10):1363-1374.
-
(1999)
J Clin Invest
, vol.104
, Issue.10
, pp. 1363-1374
-
-
Plotkin, L.I.1
Weinstein, R.S.2
Parfitt, A.M.3
Roberson, P.K.4
Manolagas, S.C.5
Bellido, T.6
-
5
-
-
14844283132
-
-
Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem. 2005 Feb 25;280:7317-7325. Epub 2004 Dec 6.
-
Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem. 2005 Feb 25;280:7317-7325. Epub 2004 Dec 6.
-
-
-
-
6
-
-
0035146537
-
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
-
Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296(2):235-242.
-
(2001)
J Pharmacol Exp Ther
, vol.296
, Issue.2
, pp. 235-242
-
-
Dunford, J.E.1
Thompson, K.2
Coxon, F.P.3
-
7
-
-
33646725498
-
-
Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7829-7834. Epub 2006 May 9.
-
Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7829-7834. Epub 2006 May 9.
-
-
-
-
8
-
-
0032559362
-
GTPases and the actin cytoskeleton
-
Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279(5350):509-514.
-
(1998)
Science
, vol.279
, Issue.5350
, pp. 509-514
-
-
Rho, H.A.1
-
9
-
-
0031977199
-
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
-
Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13(4):581-589.
-
(1998)
J Bone Miner Res
, vol.13
, Issue.4
, pp. 581-589
-
-
Luckman, S.P.1
Hughes, D.E.2
Coxon, F.P.3
Graham, R.4
Russell, G.5
Rogers, M.J.6
-
10
-
-
0036828449
-
Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis
-
Rizzoli R, Greenspan SL, Bone GIII, et al, Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. 2002;17(11):1988-1996.
-
(2002)
J Bone Miner Res
, vol.17
, Issue.11
, pp. 1988-1996
-
-
Rizzoli, R.1
Greenspan, S.L.2
GIII, B.3
-
11
-
-
0036690206
-
-
Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002 Aug;71(2):103-111. Epub 2002 Jun 27.
-
Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002 Aug;71(2):103-111. Epub 2002 Jun 27.
-
-
-
-
12
-
-
22244432201
-
Pharmacokinetics/pharmacodynamics of bisphosphonates: Use for optimisation of intermittent therapy for osteoporosis
-
Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet. 2005;44(6):551-570.
-
(2005)
Clin Pharmacokinet
, vol.44
, Issue.6
, pp. 551-570
-
-
Cremers, S.C.1
Pillai, G.2
Papapoulos, S.E.3
-
13
-
-
0037186926
-
Intravenous zoledronic acid in postmenopausal women with low bone mineral density
-
Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346(9):653-661.
-
(2002)
N Engl J Med
, vol.346
, Issue.9
, pp. 653-661
-
-
Reid, I.R.1
Brown, J.P.2
Burckhardt, P.3
-
14
-
-
34247866550
-
HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
-
Black DM, Delmas PD, Eastell R, et al, HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822.
-
(2007)
N Engl J Med
, vol.356
, Issue.18
, pp. 1809-1822
-
-
Black, D.M.1
Delmas, P.D.2
Eastell, R.3
-
15
-
-
0030766092
-
Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis
-
Khan SA, Kanis JA, Vasikaran S, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res. 1997;12(10):1700-1707.
-
(1997)
J Bone Miner Res
, vol.12
, Issue.10
, pp. 1700-1707
-
-
Khan, S.A.1
Kanis, J.A.2
Vasikaran, S.3
-
16
-
-
0029886359
-
Bisphosphonates: A review of their pharmacokinetic properties
-
Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18(2):75-85.
-
(1996)
Bone
, vol.18
, Issue.2
, pp. 75-85
-
-
Lin, J.H.1
-
17
-
-
33744774092
-
Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis
-
Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006;28(2):236-242.
-
(2006)
Clin Ther
, vol.28
, Issue.2
, pp. 236-242
-
-
Penning-van Beest, F.J.1
Goettsch, W.G.2
Erkens, J.A.3
Herings, R.M.4
-
18
-
-
33646889310
-
Osteoporosis in Clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice
-
Epub Mar 15
-
Rossini M, Bianchi G, Di Munno O, et al, Osteoporosis in Clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17(6):914-921. Epub 2006 Mar 15.
-
(2006)
Osteoporos Int. 2006
, vol.17
, Issue.6
, pp. 914-921
-
-
Rossini, M.1
Bianchi, G.2
Di Munno, O.3
-
19
-
-
10644236522
-
-
Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003 Dec;14(12):965-968. Epub 2003 Sep 19.
-
Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003 Dec;14(12):965-968. Epub 2003 Sep 19.
-
-
-
-
20
-
-
33746821808
-
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases
-
Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-1022.
-
(2006)
Mayo Clin Proc
, vol.81
, Issue.8
, pp. 1013-1022
-
-
Siris, E.S.1
Harris, S.T.2
Rosen, C.J.3
-
21
-
-
33749186614
-
Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: A cross-sectional survey
-
Epub Aug 1
-
Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int. 2006;17(11):1638-1644. Epub 2006 Aug 1.
-
(2006)
Osteoporos Int. 2006
, vol.17
, Issue.11
, pp. 1638-1644
-
-
Carr, A.J.1
Thompson, P.W.2
Cooper, C.3
-
22
-
-
0033755981
-
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
-
Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000;27(5):687-694.
-
(2000)
Bone
, vol.27
, Issue.5
, pp. 687-694
-
-
Boivin, G.Y.1
Chavassieux, P.M.2
Santora, A.C.3
Yates, J.4
Meunier, P.J.5
-
23
-
-
0037125379
-
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial
-
Rossouw JE, Anderson GL, Prentice RL, et al, Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
-
(2002)
JAMA
, vol.288
, Issue.3
, pp. 321-333
-
-
Rossouw, J.E.1
Anderson, G.L.2
Prentice, R.L.3
-
24
-
-
0004851872
-
Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
-
Black DM, Cummings SR, Karpf DB, et al, Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348(9041):1535- 1541.
-
(1996)
Lancet
, vol.348
, Issue.9041
, pp. 1535-1541
-
-
Black, D.M.1
Cummings, S.R.2
Karpf, D.B.3
-
25
-
-
0032583492
-
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
-
Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077- 2082.
-
(1998)
JAMA
, vol.280
, Issue.24
, pp. 2077-2082
-
-
Cummings, S.R.1
Black, D.M.2
Thompson, D.E.3
-
26
-
-
0033552255
-
Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
-
Harris ST, Watts NB, Genant HK, et al, Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282(14):1344-1352.
-
(1999)
JAMA
, vol.282
, Issue.14
, pp. 1344-1352
-
-
Harris, S.T.1
Watts, N.B.2
Genant, H.K.3
-
27
-
-
0035253489
-
Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women
-
McClung MR, Geusens P, Miller PD, et al, Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344(5):333-340.
-
(2001)
N Engl J Med
, vol.344
, Issue.5
, pp. 333-340
-
-
McClung, M.R.1
Geusens, P.2
Miller, P.D.3
-
28
-
-
0028851590
-
Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
-
Liberman UA, Weiss SR, Broll J, et al, Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333(22):1437-1443.
-
(1995)
N Engl J Med
, vol.333
, Issue.22
, pp. 1437-1443
-
-
Liberman, U.A.1
Weiss, S.R.2
Broll, J.3
-
29
-
-
4344580653
-
-
Delmas PD, Recker RR, Chesnut CH III, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004 Oct;15(10):792-798. Epub 2004 Apr 8.
-
Delmas PD, Recker RR, Chesnut CH III, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004 Oct;15(10):792-798. Epub 2004 Apr 8.
-
-
-
-
30
-
-
4544262219
-
-
Chesnut IC III, Skag A, Christiansen C, et al, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004 Aug;19(8):1241-1249. Epub 2004 Mar 29.
-
Chesnut IC III, Skag A, Christiansen C, et al, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004 Aug;19(8):1241-1249. Epub 2004 Mar 29.
-
-
-
-
31
-
-
0036133366
-
Bone turnover matters: The raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density [editorial]
-
Riggs BL, Melton LJ III. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density [editorial]. J Bone Miner Res. 2002;17(1):11-14.
-
(2002)
J Bone Miner Res
, vol.17
, Issue.1
, pp. 11-14
-
-
Riggs, B.L.1
Melton III, L.J.2
-
32
-
-
12144289279
-
Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women
-
Bone HG, Hosking D, Devogelaer JP, et al, Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189- 1199.
-
(2004)
N Engl J Med
, vol.350
, Issue.12
, pp. 1189-1199
-
-
Bone, H.G.1
Hosking, D.2
Devogelaer, J.P.3
-
33
-
-
0034739277
-
Alendronate for the treatment of osteoporosis in men
-
Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604-610.
-
(2000)
N Engl J Med
, vol.343
, Issue.9
, pp. 604-610
-
-
Orwoll, E.1
Ettinger, M.2
Weiss, S.3
-
34
-
-
33747682160
-
-
Finkelstein JS, Leder BZ, Burnett SM, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab. 2006 Aug;91(8):2882-2887. Epub 2006 May 9.
-
Finkelstein JS, Leder BZ, Burnett SM, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab. 2006 Aug;91(8):2882-2887. Epub 2006 May 9.
-
-
-
-
35
-
-
4544266340
-
-
Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int. 2004 Dec;15(12):992-997. Epub 2004 Jun 3.
-
Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int. 2004 Dec;15(12):992-997. Epub 2004 Jun 3.
-
-
-
-
36
-
-
33845890326
-
FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial
-
Black DM, Schwartz AV, Ensrud KE, et al, FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-2938.
-
(2006)
JAMA
, vol.296
, Issue.24
, pp. 2927-2938
-
-
Black, D.M.1
Schwartz, A.V.2
Ensrud, K.E.3
-
37
-
-
37349045347
-
-
Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone. 2008 Jan;42(1):36-42. Epub 2004 Jun 3.
-
Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone. 2008 Jan;42(1):36-42. Epub 2004 Jun 3.
-
-
-
-
38
-
-
35748967004
-
-
Lyles KW, Colon-Emeric CS, Magaziner JS, et al, HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 Nov 1;357(18):1799-1809. Epub 2007 Sep 17.
-
Lyles KW, Colon-Emeric CS, Magaziner JS, et al, HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 Nov 1;357(18):1799-1809. Epub 2007 Sep 17.
-
-
-
-
39
-
-
34250165747
-
-
McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007 Jul;41(1):122-128. Epub 2007 Mar 24.
-
McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007 Jul;41(1):122-128. Epub 2007 Mar 24.
-
-
-
-
40
-
-
0037016032
-
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: A randomized, double-blind, placebo-controlled trial
-
Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137(11):875-883.
-
(2002)
Ann Intern Med
, vol.137
, Issue.11
, pp. 875-883
-
-
Greenspan, S.L.1
Emkey, R.D.2
Bone, H.G.3
-
41
-
-
0036268714
-
Combination therapy for postmenopausal osteoporosis
-
Compston JE, Watts NB. Combination therapy for postmenopausal osteoporosis. Clin Endocrinol (Oxf). 2002;56(5):565-569.
-
(2002)
Clin Endocrinol (Oxf)
, vol.56
, Issue.5
, pp. 565-569
-
-
Compston, J.E.1
Watts, N.B.2
-
42
-
-
0027985064
-
Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency
-
Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med. 1994;331(24):1618-1623.
-
(1994)
N Engl J Med
, vol.331
, Issue.24
, pp. 1618-1623
-
-
Finkelstein, J.S.1
Klibanski, A.2
Schaefer, E.H.3
Hornstein, M.D.4
Schiff, I.5
Neer, R.M.6
-
43
-
-
0035837553
-
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
-
Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441.
-
(2001)
N Engl J Med
, vol.344
, Issue.19
, pp. 1434-1441
-
-
Neer, R.M.1
Arnaud, C.D.2
Zanchetta, J.R.3
-
44
-
-
23444435838
-
Daily and cyclic parathyroid hormone in women receiving alendronate
-
Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005;353(6):566-575.
-
(2005)
N Engl J Med
, vol.353
, Issue.6
, pp. 566-575
-
-
Cosman, F.1
Nieves, J.2
Zion, M.3
Woelfert, L.4
Luckey, M.5
Lindsay, R.6
-
45
-
-
0141684971
-
-
Black DM, Greenspan SL, Ensrud KE, et al, PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1207-1215. Epub 2003 Sep 20.
-
Black DM, Greenspan SL, Ensrud KE, et al, PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1207-1215. Epub 2003 Sep 20.
-
-
-
-
46
-
-
0141796739
-
-
Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1216-1226. Epub 2003 Sep 20.
-
Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1216-1226. Epub 2003 Sep 20.
-
-
-
-
47
-
-
0034458020
-
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
-
Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000;85(6):2129-2134.
-
(2000)
J Clin Endocrinol Metab
, vol.85
, Issue.6
, pp. 2129-2134
-
-
Rittmaster, R.S.1
Bolognese, M.2
Ettinger, M.P.3
-
48
-
-
23444452077
-
PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
-
Black DM, Bilezikian JP, Ensrud KE, et al, PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353(6):555-565.
-
(2005)
N Engl J Med
, vol.353
, Issue.6
, pp. 555-565
-
-
Black, D.M.1
Bilezikian, J.P.2
Ensrud, K.E.3
-
49
-
-
34047152266
-
Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: A prospective randomized trial
-
Curtis JR, Westfall AO, Allison J, et al. Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial. Arch Intern Med. 2007;167(6):591-596.
-
(2007)
Arch Intern Med
, vol.167
, Issue.6
, pp. 591-596
-
-
Curtis, J.R.1
Westfall, A.O.2
Allison, J.3
-
50
-
-
33747363453
-
STOP Investigators. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis
-
de Nijs RN, Jacobs JW, Lems WF, et al, STOP Investigators. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355(7):675-684.
-
(2006)
N Engl J Med
, vol.355
, Issue.7
, pp. 675-684
-
-
de Nijs, R.N.1
Jacobs, J.W.2
Lems, W.F.3
-
51
-
-
33847386303
-
-
van Staa TP, Geusens P, Zhang B, Leufkens HG, Boonen A, Cooper C. Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. Rheumatology (Oxford). 2007 Mar;46 (3):460-466. Epub 2006 Aug 9.
-
van Staa TP, Geusens P, Zhang B, Leufkens HG, Boonen A, Cooper C. Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. Rheumatology (Oxford). 2007 Mar;46 (3):460-466. Epub 2006 Aug 9.
-
-
-
-
52
-
-
0030931764
-
Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial
-
Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int. 1997;61(4):266-271.
-
(1997)
Calcif Tissue Int
, vol.61
, Issue.4
, pp. 266-271
-
-
Boutsen, Y.1
Jamart, J.2
Esselinckx, W.3
Stoffel, M.4
Devogelaer, J.P.5
-
53
-
-
0345308466
-
-
Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroidinduced osteoporosis: results from a long-term comparative study. Osteoporos Int. 2003 Oct;14(10):801-807. Epub 2003 Aug 28.
-
Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroidinduced osteoporosis: results from a long-term comparative study. Osteoporos Int. 2003 Oct;14(10):801-807. Epub 2003 Aug 28.
-
-
-
-
54
-
-
0035086121
-
Intravenous pamidronate as treatment for osteoporosis after heart transplantation: A prospective study
-
Krieg MA, Seydoux C, Sandini L, et al. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos Int. 2001;12(2):112-116.
-
(2001)
Osteoporos Int
, vol.12
, Issue.2
, pp. 112-116
-
-
Krieg, M.A.1
Seydoux, C.2
Sandini, L.3
-
55
-
-
10744232811
-
Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate
-
Coco M, Glicklich D, Faugere MC, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003;14(10):2669-2676.
-
(2003)
J Am Soc Nephrol
, vol.14
, Issue.10
, pp. 2669-2676
-
-
Coco, M.1
Glicklich, D.2
Faugere, M.C.3
-
56
-
-
0033834376
-
Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation
-
Aris RM, Lester GE, Renner JB, et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med. 2000;162(3)(pt 1):941-946.
-
(2000)
Am J Respir Crit Care Med
, vol.162
, Issue.3 PART 1
, pp. 941-946
-
-
Aris, R.M.1
Lester, G.E.2
Renner, J.B.3
-
57
-
-
0034921633
-
Effect of ibandronate on bone loss and renal function after kidney transplantation
-
Grotz W, Nagel C, Poeschel D, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001;12 (7):1530-1537.
-
(2001)
J Am Soc Nephrol
, vol.12
, Issue.7
, pp. 1530-1537
-
-
Grotz, W.1
Nagel, C.2
Poeschel, D.3
-
58
-
-
0034778617
-
Alendronate prevents further bone loss in renal transplant recipients
-
Giannini S, D'Angelo A, Carraro G, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res. 2001;16(11):2111-2117.
-
(2001)
J Bone Miner Res
, vol.16
, Issue.11
, pp. 2111-2117
-
-
Giannini, S.1
D'Angelo, A.2
Carraro, G.3
-
59
-
-
14044263654
-
-
Tauchmanova L, Ricci P, Serio B, et al. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2005 Feb;90(2):627-634. Epub 2004 Nov 16.
-
Tauchmanova L, Ricci P, Serio B, et al. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2005 Feb;90(2):627-634. Epub 2004 Nov 16.
-
-
-
-
60
-
-
33749580962
-
-
Grigg AP, Shuttleworth P, Reynolds J, et al. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2006 Oct;91(10):3835-3843. Epub 2006 Jul 11.
-
Grigg AP, Shuttleworth P, Reynolds J, et al. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2006 Oct;91(10):3835-3843. Epub 2006 Jul 11.
-
-
-
-
61
-
-
33746812696
-
Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation
-
D'Souza AB, Grigg AP, Szer J, Ebeling PR. Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation. Intern Med J. 2006;36(9):600-603.
-
(2006)
Intern Med J
, vol.36
, Issue.9
, pp. 600-603
-
-
D'Souza, A.B.1
Grigg, A.P.2
Szer, J.3
Ebeling, P.R.4
-
62
-
-
40249094784
-
-
Yao S, McCarthy PL, Dunford LM, et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplant. 2008 Feb;41(4):393-398. Epub 2007 Nov 12.
-
Yao S, McCarthy PL, Dunford LM, et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplant. 2008 Feb;41(4):393-398. Epub 2007 Nov 12.
-
-
-
-
63
-
-
36148958951
-
Teriparatide or alendronate in glucocorticoid-induced osteoporosis
-
Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028- 2039.
-
(2007)
N Engl J Med
, vol.357
, Issue.20
, pp. 2028-2039
-
-
Saag, K.G.1
Shane, E.2
Boonen, S.3
-
64
-
-
34147138506
-
-
Gilchrist NL, Frampton CM, Acland RH, et al. Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2007 Apr;92(4):1385-1390. Epub 2007 Jan 16.
-
Gilchrist NL, Frampton CM, Acland RH, et al. Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2007 Apr;92(4):1385-1390. Epub 2007 Jan 16.
-
-
-
-
65
-
-
0032978038
-
Intravenous pamidronate attenuates bone density loss after acute spinal cord injury
-
Nance PW, Schryvers O, Leslie W, Ludwig S, Krahn J, Uebelhart D. Intravenous pamidronate attenuates bone density loss after acute spinal cord injury. Arch Phys Med Rehabil. 1999;80(3):243-251.
-
(1999)
Arch Phys Med Rehabil
, vol.80
, Issue.3
, pp. 243-251
-
-
Nance, P.W.1
Schryvers, O.2
Leslie, W.3
Ludwig, S.4
Krahn, J.5
Uebelhart, D.6
-
66
-
-
0034773441
-
Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: A prospective randomized study
-
Venesmaa PK, Kroger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhav EM. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res. 2001;16(11):2126-2131.
-
(2001)
J Bone Miner Res
, vol.16
, Issue.11
, pp. 2126-2131
-
-
Venesmaa, P.K.1
Kroger, H.P.2
Miettinen, H.J.3
Jurvelin, J.S.4
Suomalainen, O.T.5
Alhav, E.M.6
-
67
-
-
34249977632
-
-
Yamasaki S, Masuhara K, Yamaguchi K, Nakai T, Fuji T, Seino Y. Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. Osteoporos Int. 2007 Jul;18(7):1009-1015. Epub 2007 Feb 15.
-
Yamasaki S, Masuhara K, Yamaguchi K, Nakai T, Fuji T, Seino Y. Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. Osteoporos Int. 2007 Jul;18(7):1009-1015. Epub 2007 Feb 15.
-
-
-
-
68
-
-
33746897394
-
Paget's disease of bone
-
Whyte MP. Paget's disease of bone. N Engl J Med. 2006;355(6):593-600.
-
(2006)
N Engl J Med
, vol.355
, Issue.6
, pp. 593-600
-
-
Whyte, M.P.1
-
69
-
-
9044220965
-
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone
-
Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab. 1996;81(3):961-967.
-
(1996)
J Clin Endocrinol Metab
, vol.81
, Issue.3
, pp. 961-967
-
-
Siris, E.1
Weinstein, R.S.2
Altman, R.3
-
70
-
-
15144345644
-
Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study
-
Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res. 1998;13(6):1032-1038.
-
(1998)
J Bone Miner Res
, vol.13
, Issue.6
, pp. 1032-1038
-
-
Siris, E.S.1
Chines, A.A.2
Altman, R.D.3
-
71
-
-
0028202861
-
Perspectives: A practical guide to the use of pamidronate in the treatment of Paget's disease
-
Siris ES. Perspectives: a practical guide to the use of pamidronate in the treatment of Paget's disease. J Bone Miner Res. 1994;9(3):303-304.
-
(1994)
J Bone Miner Res
, vol.9
, Issue.3
, pp. 303-304
-
-
Siris, E.S.1
-
72
-
-
24044431619
-
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease
-
Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353(9):898-908.
-
(2005)
N Engl J Med
, vol.353
, Issue.9
, pp. 898-908
-
-
Reid, I.R.1
Miller, P.2
Lyles, K.3
-
73
-
-
33750681754
-
Treatment and prevention of bone metastases and myeloma in bone disease
-
Favus MJ, ed, 6th ed. Washington, DC: American Society for Bone and Mineral Research;
-
Body JJ. Treatment and prevention of bone metastases and myeloma in bone disease. In: Favus MJ, ed. Primer on the Metabolic Diseases and Disorders of Mineral Metabolism. 6th ed. Washington, DC: American Society for Bone and Mineral Research; 2006:383-390.
-
(2006)
Primer on the Metabolic Diseases and Disorders of Mineral Metabolism
, pp. 383-390
-
-
Body, J.J.1
-
74
-
-
10544228130
-
Protocol 19 Aredia Breast Cancer Study Group. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
-
Hortobagyi GN, Theriault RL, Porter L, et al, Protocol 19 Aredia Breast Cancer Study Group. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996;335(24):1785-1791.
-
(1996)
N Engl J Med
, vol.335
, Issue.24
, pp. 1785-1791
-
-
Hortobagyi, G.N.1
Theriault, R.L.2
Porter, L.3
-
75
-
-
7144223389
-
Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
-
Hortobagyi GN, Theriault RL, Lipton A, et al, Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol. 1998;16(6):2038-2044.
-
(1998)
J Clin Oncol
, vol.16
, Issue.6
, pp. 2038-2044
-
-
Hortobagyi, G.N.1
Theriault, R.L.2
Lipton, A.3
-
76
-
-
0034162528
-
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials
-
Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88(5):1082-1090.
-
(2000)
Cancer
, vol.88
, Issue.5
, pp. 1082-1090
-
-
Lipton, A.1
Theriault, R.L.2
Hortobagyi, G.N.3
-
77
-
-
2642521168
-
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial
-
Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613-2621.
-
(2004)
Cancer
, vol.100
, Issue.12
, pp. 2613-2621
-
-
Rosen, L.S.1
Gordon, D.2
Tchekmedyian, N.S.3
-
78
-
-
33750605957
-
-
Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol. 2006 Oct 20;24(30):4895-4900. Epub 2006 Sep 25.
-
Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol. 2006 Oct 20;24(30):4895-4900. Epub 2006 Sep 25.
-
-
-
-
79
-
-
17144447171
-
MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases
-
Body JJ, Diel IJ, Lichinitser MR, et al, MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14(9):1399-1405.
-
(2003)
Ann Oncol
, vol.14
, Issue.9
, pp. 1399-1405
-
-
Body, J.J.1
Diel, I.J.2
Lichinitser, M.R.3
-
80
-
-
4444337297
-
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer
-
Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain. 2004;111(3):306-312.
-
(2004)
Pain
, vol.111
, Issue.3
, pp. 306-312
-
-
Body, J.J.1
Diel, I.J.2
Bell, R.3
-
81
-
-
1942501727
-
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies
-
Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004;90(6):1133-1137.
-
(2004)
Br J Cancer
, vol.90
, Issue.6
, pp. 1133-1137
-
-
Body, J.J.1
Diel, I.J.2
Lichinitzer, M.3
-
82
-
-
0036682211
-
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer
-
Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002;20(15):3219-3224.
-
(2002)
J Clin Oncol
, vol.20
, Issue.15
, pp. 3219-3224
-
-
Powles, T.1
Paterson, S.2
Kanis, J.A.3
-
83
-
-
51349126647
-
Cancer treatment-related bone loss: A review and synthesis of the literature
-
Khan MN, Khan AA. Cancer treatment-related bone loss: a review and synthesis of the literature. Curr Oncol. 2008;15(suppl 1):S30-S40.
-
(2008)
Curr Oncol
, vol.15
, Issue.SUPPL. 1
-
-
Khan, M.N.1
Khan, A.A.2
-
84
-
-
33947539707
-
-
Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007 Mar 1;25(7):820-828. Epub 2006 Dec 11.
-
Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007 Mar 1;25(7):820-828. Epub 2006 Dec 11.
-
-
-
-
85
-
-
34547569748
-
-
Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole: prevention with bisphosphonates. Bone. 2007 Sep;41(3):346-352. Epub 2007 Jun 16.
-
Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole: prevention with bisphosphonates. Bone. 2007 Sep;41(3):346-352. Epub 2007 Jun 16.
-
-
-
-
86
-
-
0033962103
-
Markers of bone turnover for the management of patients with bone metastases from prostate cancer
-
Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000;82(4):858-864.
-
(2000)
Br J Cancer
, vol.82
, Issue.4
, pp. 858-864
-
-
Garnero, P.1
Buchs, N.2
Zekri, J.3
Rizzoli, R.4
Coleman, R.E.5
Delmas, P.D.6
-
87
-
-
0037009822
-
Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
-
Saad F, Gleason DM, Murray R, et al, Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-1468.
-
(2002)
J Natl Cancer Inst
, vol.94
, Issue.19
, pp. 1458-1468
-
-
Saad, F.1
Gleason, D.M.2
Murray, R.3
-
88
-
-
2942518111
-
Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
-
Saad F, Gleason DM, Murray R, et al, Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-882.
-
(2004)
J Natl Cancer Inst
, vol.96
, Issue.11
, pp. 879-882
-
-
Saad, F.1
Gleason, D.M.2
Murray, R.3
-
89
-
-
0035960116
-
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer
-
Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345(13):948-955.
-
(2001)
N Engl J Med
, vol.345
, Issue.13
, pp. 948-955
-
-
Smith, M.R.1
McGovern, F.J.2
Zietman, A.L.3
-
90
-
-
34047237418
-
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer
-
Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25(9):1038-1042.
-
(2007)
J Clin Oncol
, vol.25
, Issue.9
, pp. 1038-1042
-
-
Michaelson, M.D.1
Kaufman, D.S.2
Lee, H.3
-
91
-
-
0038075478
-
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
-
Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169(6):2008-2012.
-
(2003)
J Urol
, vol.169
, Issue.6
, pp. 2008-2012
-
-
Smith, M.R.1
Eastham, J.2
Gleason, D.M.3
Shasha, D.4
Tchekmedyian, S.5
Zinner, N.6
-
92
-
-
36349002794
-
Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer
-
Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol. 2007;14(12):1071-1075.
-
(2007)
Int J Urol
, vol.14
, Issue.12
, pp. 1071-1075
-
-
Ishizaka, K.1
Machida, T.2
Kobayashi, S.3
Kanbe, N.4
Kitahara, S.5
Yoshida, K.6
-
93
-
-
9044219839
-
Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
-
Berenson JR, Lichtenstein A, Porter L, et al, Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:488-493.
-
(1996)
N Engl J Med
, vol.334
, pp. 488-493
-
-
Berenson, J.R.1
Lichtenstein, A.2
Porter, L.3
-
94
-
-
0035312469
-
-
Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases [published correction appears in Cancer. 2001;91(10):1956]. Cancer. 2001;91(7):1191-1200.
-
Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases [published correction appears in Cancer. 2001;91(10):1956]. Cancer. 2001;91(7):1191-1200.
-
-
-
-
95
-
-
0035463593
-
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial
-
Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377-387.
-
(2001)
Cancer J
, vol.7
, Issue.5
, pp. 377-387
-
-
Rosen, L.S.1
Gordon, D.2
Kaminski, M.3
-
96
-
-
0036729485
-
American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma
-
Berenson JR, Hillner BE, Kyle RA, et al, American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20(17):3719-3736.
-
(2002)
J Clin Oncol
, vol.20
, Issue.17
, pp. 3719-3736
-
-
Berenson, J.R.1
Hillner, B.E.2
Kyle, R.A.3
-
97
-
-
33746855407
-
Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma
-
Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81(8):1047-1053.
-
(2006)
Mayo Clin Proc
, vol.81
, Issue.8
, pp. 1047-1053
-
-
Lacy, M.Q.1
Dispenzieri, A.2
Gertz, M.A.3
-
98
-
-
34047200362
-
Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement [letter]
-
Durie BGM. Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement [letter]. Mayo Clin Proc. 2007;82(4):516-517.
-
(2007)
Mayo Clin Proc
, vol.82
, Issue.4
, pp. 516-517
-
-
Durie, B.G.M.1
-
99
-
-
0041386301
-
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma
-
Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98(5):962-969.
-
(2003)
Cancer
, vol.98
, Issue.5
, pp. 962-969
-
-
Lipton, A.1
Zheng, M.2
Seaman, J.3
-
100
-
-
33947168658
-
Experience with bisphosphonates in osteogenesis imperfecta
-
Glorieux FH. Experience with bisphosphonates in osteogenesis imperfecta. Pediatrics. 2007;119(suppl 2):S163-S165.
-
(2007)
Pediatrics
, vol.119
, Issue.SUPPL. 2
-
-
Glorieux, F.H.1
-
101
-
-
0036841117
-
The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta
-
Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest. 2002;110(9):1293-1299.
-
(2002)
J Clin Invest
, vol.110
, Issue.9
, pp. 1293-1299
-
-
Rauch, F.1
Travers, R.2
Plotkin, H.3
Glorieux, F.H.4
-
102
-
-
24144474226
-
Efficacy of oral alendronate in children with osteogenesis imperfecta
-
Cho TJ, Choi IH, Chung CY, Yoo WJ, Park MS, Park YK. Efficacy of oral alendronate in children with osteogenesis imperfecta. J Pediatr Orthop. 2005;25(5):607-612.
-
(2005)
J Pediatr Orthop
, vol.25
, Issue.5
, pp. 607-612
-
-
Cho, T.J.1
Choi, I.H.2
Chung, C.Y.3
Yoo, W.J.4
Park, M.S.5
Park, Y.K.6
-
103
-
-
29644443435
-
-
DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res. 2006 Jan;21(1):132-140. Epub 2005 Oct 17.
-
DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res. 2006 Jan;21(1):132-140. Epub 2005 Oct 17.
-
-
-
-
104
-
-
40349084107
-
Alendronate treatment in children with osteogenesis imperfecta
-
Akcay T, Turan S, Guran T, Bereket A. Alendronate treatment in children with osteogenesis imperfecta. Indian Pediatr. 2008;45(2):105-109.
-
(2008)
Indian Pediatr
, vol.45
, Issue.2
, pp. 105-109
-
-
Akcay, T.1
Turan, S.2
Guran, T.3
Bereket, A.4
-
105
-
-
0037371391
-
Modern approach to children with osteogenesis imperfecta
-
Zeitlin L, Fassier F, Glorieux FH. Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B. 2003;12(2):77-87.
-
(2003)
J Pediatr Orthop B
, vol.12
, Issue.2
, pp. 77-87
-
-
Zeitlin, L.1
Fassier, F.2
Glorieux, F.H.3
-
106
-
-
20844452409
-
-
Munns CF, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res. 2005 Jul;20(7):1235-1243. Epub 2005 Feb 21.
-
Munns CF, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res. 2005 Jul;20(7):1235-1243. Epub 2005 Feb 21.
-
-
-
-
107
-
-
42549115642
-
Bisphosphonate therapy for children and adolescents with secondary osteoporosis
-
CD005324
-
Ward L, Tricco AC, Phuong P, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev. 2007;(4):CD005324.
-
(2007)
Cochrane Database Syst Rev
, Issue.4
-
-
Ward, L.1
Tricco, A.C.2
Phuong, P.3
-
108
-
-
35148881181
-
Consensus and controversy regarding osteoporosis in the pediatric population
-
Bachrach LK. Consensus and controversy regarding osteoporosis in the pediatric population. Endocr Pract. 2007;13(5):513-520.
-
(2007)
Endocr Pract
, vol.13
, Issue.5
, pp. 513-520
-
-
Bachrach, L.K.1
-
109
-
-
33847734705
-
Prolonged bisphosphonate release after treatment in children [letter]
-
Papapoulos SE, Cremers SC. Prolonged bisphosphonate release after treatment in children [letter]. N Engl J Med. 2007;356(10):1075-1076.
-
(2007)
N Engl J Med
, vol.356
, Issue.10
, pp. 1075-1076
-
-
Papapoulos, S.E.1
Cremers, S.C.2
-
110
-
-
21344456854
-
-
Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res. 2004 Oct;19(10):1742-1745. Epub 2004 Jul 21.
-
Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res. 2004 Oct;19(10):1742-1745. Epub 2004 Jul 21.
-
-
-
-
111
-
-
33646836925
-
-
Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med. 2006; 145(3):235]. Ann Intern Med. 2006;144(10):753-761.
-
Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med. 2006; 145(3):235]. Ann Intern Med. 2006;144(10):753-761.
-
-
-
-
112
-
-
33745792743
-
-
Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006 Jul;91(7):968-971. Epub 2006 Jun 1.
-
Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006 Jul;91(7):968-971. Epub 2006 Jun 1.
-
-
-
-
113
-
-
34250313823
-
-
Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia. 2007 Jul;21(7):1545-1548. Epub 2007 Apr 5.
-
Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia. 2007 Jul;21(7):1545-1548. Epub 2007 Apr 5.
-
-
-
-
114
-
-
34848841461
-
Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research [editorial]
-
Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research [editorial]. J Bone Miner Res. 2007;22(10):1479-1491.
-
(2007)
J Bone Miner Res
, vol.22
, Issue.10
, pp. 1479-1491
-
-
Khosla, S.1
Burr, D.2
Cauley, J.3
-
115
-
-
27344453813
-
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment
-
Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63(11):1567-1575.
-
(2005)
J Oral Maxillofac Surg
, vol.63
, Issue.11
, pp. 1567-1575
-
-
Marx, R.E.1
Sawatari, Y.2
Fortin, M.3
Broumand, V.4
-
116
-
-
33644841755
-
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors
-
Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23(34):8580-8587.
-
(2005)
J Clin Oncol
, vol.23
, Issue.34
, pp. 8580-8587
-
-
Bamias, A.1
Kastritis, E.2
Bamia, C.3
-
117
-
-
33845234810
-
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone [letter]
-
Tosi P, Zamagni E, Cangini D, et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone [letter]. Blood. 2006;108(12):3951-3952.
-
(2006)
Blood
, vol.108
, Issue.12
, pp. 3951-3952
-
-
Tosi, P.1
Zamagni, E.2
Cangini, D.3
-
118
-
-
33751528987
-
Osteonecrosis of the jaw - do bisphosphonates pose a risk?
-
Bilezikian JP. Osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl J Med. 2006;355(22):2278-2281.
-
(2006)
N Engl J Med
, vol.355
, Issue.22
, pp. 2278-2281
-
-
Bilezikian, J.P.1
-
119
-
-
0042861578
-
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic [letter]
-
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic [letter]. J Oral Maxillofac Surg. 2003;61(9):1115-1117.
-
(2003)
J Oral Maxillofac Surg
, vol.61
, Issue.9
, pp. 1115-1117
-
-
Marx, R.E.1
-
120
-
-
34247892446
-
Alendronate and atrial fibrillation [letter]
-
Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation [letter]. N Engl J Med. 2007;356(18):1895-1896.
-
(2007)
N Engl J Med
, vol.356
, Issue.18
, pp. 1895-1896
-
-
Cummings, S.R.1
Schwartz, A.V.2
Black, D.M.3
-
121
-
-
42949145038
-
Use of alendronate and risk of incident atrial fibrillation in women
-
Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008;168(8):826-831.
-
(2008)
Arch Intern Med
, vol.168
, Issue.8
, pp. 826-831
-
-
Heckbert, S.R.1
Li, G.2
Cummings, S.R.3
Smith, N.L.4
Psaty, B.M.5
-
122
-
-
42249109858
-
-
Sorensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008 Apr 12;336(7648):813-816. Epub 2008 Mar 11.
-
Sorensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008 Apr 12;336(7648):813-816. Epub 2008 Mar 11.
-
-
-
-
123
-
-
34547944533
-
Yearly zoledronic acid in postmenopausal osteoporosis [letter]
-
Karam R, Camm J, McClung M. Yearly zoledronic acid in postmenopausal osteoporosis [letter]. N Engl J Med. 2007;357(7):712-713.
-
(2007)
N Engl J Med
, vol.357
, Issue.7
, pp. 712-713
-
-
Karam, R.1
Camm, J.2
McClung, M.3
-
124
-
-
0346366454
-
Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs
-
Burr DB, Miller L, Grynpas M, et al. Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone. 2003;33(6):960-969.
-
(2003)
Bone
, vol.33
, Issue.6
, pp. 960-969
-
-
Burr, D.B.1
Miller, L.2
Grynpas, M.3
-
125
-
-
36549086149
-
Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: A bone biopsy study
-
Chapurlat RD, Arlot M, Burt-Pichat B, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res. 2007;22(10):1502-1509.
-
(2007)
J Bone Miner Res
, vol.22
, Issue.10
, pp. 1502-1509
-
-
Chapurlat, R.D.1
Arlot, M.2
Burt-Pichat, B.3
-
126
-
-
15944413442
-
-
Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005 Mar;90(3):1294-1301. Epub 2004 Dec 14.
-
Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005 Mar;90(3):1294-1301. Epub 2004 Dec 14.
-
-
-
-
127
-
-
33750742219
-
Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis [letter]
-
Armamento-Villareal R, Napoli N, Panwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis [letter]. N Engl J Med. 2006;355(19):2048-2050.
-
(2006)
N Engl J Med
, vol.355
, Issue.19
, pp. 2048-2050
-
-
Armamento-Villareal, R.1
Napoli, N.2
Panwar, V.3
Novack, D.4
-
128
-
-
33748171925
-
-
Whitson HE, Lobaugh B, Lyles KW. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone. Bone. 2006 Oct;39(4):954-958. Epub 2006 Jun 12.
-
Whitson HE, Lobaugh B, Lyles KW. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone. Bone. 2006 Oct;39(4):954-958. Epub 2006 Jun 12.
-
-
-
-
129
-
-
0036441362
-
Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions [letter]
-
Jones SG, Dolan G, Lengyel K, Myers B. Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions [letter]. Br J Haematol. 2002;119(2):576-577.
-
(2002)
Br J Haematol
, vol.119
, Issue.2
, pp. 576-577
-
-
Jones, S.G.1
Dolan, G.2
Lengyel, K.3
Myers, B.4
-
130
-
-
0035002570
-
Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism
-
Mishra A, Wong L, Jonklaas J. Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. Endocrine. 2001;14(2):159-164.
-
(2001)
Endocrine
, vol.14
, Issue.2
, pp. 159-164
-
-
Mishra, A.1
Wong, L.2
Jonklaas, J.3
-
131
-
-
33646837806
-
Bisphosphonate- induced hypocalcemia: Report of 3 cases and review of literature
-
Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate- induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract. 2006;12(1):48-53.
-
(2006)
Endocr Pract
, vol.12
, Issue.1
, pp. 48-53
-
-
Maalouf, N.M.1
Heller, H.J.2
Odvina, C.V.3
Kim, P.J.4
Sakhaee, K.5
-
132
-
-
11244311877
-
The bisphosphonate acute phase response: Rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins
-
Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005;139(1):101-111.
-
(2005)
Clin Exp Immunol
, vol.139
, Issue.1
, pp. 101-111
-
-
Hewitt, R.E.1
Lissina, A.2
Green, A.E.3
Slay, E.S.4
Price, D.A.5
Sewell, A.K.6
-
133
-
-
29044443123
-
-
Barrera BA, Wilton L, Harris S, Shakir SA. Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England. Osteoporos Int. 2005 Dec;16(12):1989-1998. Epub 2005 Aug 31.
-
Barrera BA, Wilton L, Harris S, Shakir SA. Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England. Osteoporos Int. 2005 Dec;16(12):1989-1998. Epub 2005 Aug 31.
-
-
-
-
134
-
-
67549104437
-
-
and, January 7, 2008, Accessed July 18, 2008
-
US Food and Drug Administration. Information on bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa). January 7, 2008. http://ovha.vermont.gov/for-providers/ i3a_fda_gov_cder_drug_infopage_bisphosphonates_default.pdf. Accessed July 18, 2008.
-
Information on bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)
-
-
Food, U.S.1
-
135
-
-
13444260767
-
Alendronate and risedronate: Reports of severe bone, joint, and muscle pain [letter]
-
Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain [letter]. Arch Intern Med. 2005;165(3):346-347.
-
(2005)
Arch Intern Med
, vol.165
, Issue.3
, pp. 346-347
-
-
Wysowski, D.K.1
Chang, J.T.2
-
136
-
-
0347135841
-
Pamidronate-induced nephrotoxic tubular necrosis - a case report
-
Smetana S, Michlin A, Rosenman E, Biro A, Boaz M, Katzir Z. Pamidronate-induced nephrotoxic tubular necrosis - a case report. Clin Nephrol. 2004;61(1):63-67.
-
(2004)
Clin Nephrol
, vol.61
, Issue.1
, pp. 63-67
-
-
Smetana, S.1
Michlin, A.2
Rosenman, E.3
Biro, A.4
Boaz, M.5
Katzir, Z.6
-
137
-
-
0142025453
-
Renal failure with the use of zoledronic acid [letter]
-
Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid [letter]. N Engl J Med. 2003(17);349:1676-1679.
-
(2003)
N Engl J Med
, vol.349
, Issue.17
, pp. 1676-1679
-
-
Chang, J.T.1
Green, L.2
Beitz, J.3
-
138
-
-
34247627002
-
Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: A randomized controlled trial
-
Barone A, Giusti A, Pioli G, et al. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc. 2007;55(5):752-757.
-
(2007)
J Am Geriatr Soc
, vol.55
, Issue.5
, pp. 752-757
-
-
Barone, A.1
Giusti, A.2
Pioli, G.3
-
139
-
-
34447514029
-
Vitamin D deficiency
-
Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281.
-
(2007)
N Engl J Med
, vol.357
, Issue.3
, pp. 266-281
-
-
Holick, M.F.1
-
140
-
-
0028766715
-
Optimal calcium intake
-
Accessed July 18, 2008
-
National Institutes of Health. Optimal calcium intake. NIH Consens Statement. 1994;12(4):1-31. http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid= hstat4.chapter.13595. Accessed July 18, 2008.
-
(1994)
NIH Consens Statement
, vol.12
, Issue.4
, pp. 1-31
-
-
-
141
-
-
84900362155
-
-
National Osteoporosis Foundation's Updated Recommendations for Calcium and Vitamin D Intake; July 26, 2007. http://216.247.61.108/prevention/ calcium_and_VitaminD.htm . Accessed July 18, 2008.
-
National Osteoporosis Foundation's Updated Recommendations for Calcium and Vitamin D Intake; July 26, 2007. http://216.247.61.108/prevention/ calcium_and_VitaminD.htm . Accessed July 18, 2008.
-
-
-
-
142
-
-
84900367750
-
-
Dietary Reference Intakes (DRIs): Summary Tables; 2004.
-
Dietary Reference Intakes (DRIs): Summary Tables; 2004.
-
-
-
|